Pregabalin's abuse potential: A mini review focusing on the pharmacological profile

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 8, 2014, Pages 709-716

  Papazisis, Georgios ^a   Tzachanis, Dimitrios ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Abuse potential; Gabapentin; Pregabalin; Substance seeking behavior; 2 ligands

Indexed keywords

ANALGESICS; ANIMALS; BEHAVIOR, ADDICTIVE; GAMMA-AMINOBUTYRIC ACID; HUMANS; NEURONS; PHYSICIAN'S PRACTICE PATTERNS; SUBSTANCE-RELATED DISORDERS;

EID: 84905869342     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202118     Document Type: Review

References (67)

1. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Göthert M. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002; 42: 229-236. CrossRef PubMed (Pubitemid 34137026)
2. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000; 295: 1086-1093. PubMed
3. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003; 105: 133-141. CrossRef PubMed (Pubitemid 37162482)
4. EMA. Initial scientific discussion for the approval of Lyrica, 2004. Available from:http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Scientific-Discussion/human/000546/WC500046600.pdf (accessed on December 5, 2013).
5. Pfizer. Highlights of prescribing information: Lyrica. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=561 (accessed on December 15, 2013).
6. Kavoussi R. Pregabalin: From molecule to medicine. Eur Neuropsychopharmacol. 2006; 16 (Suppl 2): S128-S133. CrossRef PubMed (Pubitemid 43947553)
7. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Medical review(s). In: Lyrica (pregabalin) capsules. Company: Pfizer, Inc. Application No.:21-446. Rockville (MD): Food and Drug Administration; (FDA drug approval package). 2004. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/021446-Lyrica%20Capsules- medr.pdf (accessed on November 15, 2013).
8. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist. 2005; 70: 43633-43635. PubMed
9. EMCDDA-Europol. Annual Report on the implementation of Council Decision 2005/387/JHA; Annex 2-New psychoactive substances reported to the EMCDDA and Europol 9 for the first time in 2009 under the terms of Council, 2009. Available from: http://www.emcdda.europa.eu/html.cfm/index33227EN.html (accessed on November 21, 2013).
10. Health IMS. Top 20 Global products, 2012. Available from: http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/ Press%20Room/Top-Line%20Market%20Data%20&%20Trends/Top-20-Global-Products- 2012-2.pdf (accessed on December 21, 2013).
11. Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin - results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010; 66: 947-953. CrossRef PubMed
12. Schifano F, D'Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farré M, Flesland L, Mannonen M, Majava A, Pagani S, Peltoniemi T, Siemann H, Skutle A, Torrens M, Pezzolesi C, van der Kreeft P, Scherbaum N. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011; 80: 118-122. CrossRef PubMed
13. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, Mann K. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry. 2010; 167: 869. CrossRef PubMed
14. Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010; 110: 605-607. PubMed
15. Zacny JP, Paice JA, Coalson DW. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav. 2012; 100: 560-565. CrossRef PubMed
16. Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013; 69: 1335-1342. CrossRef PubMed
17. Millar J, Sadasivan S, Weatherup N, Lutton S. Lyrica nights-recreational pregabalin abuse in an urban emergency department. Emerg Med J. 2013; 30: 874. CrossRef
18. Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, Wagner X, Kiefer F, Hermann D. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013; 69: 2021-2025. PubMed
19. Papazisis G, Garyfallos G, Sardeli C, Kouvelas D. Pregabalin abuse after past substance-seeking behavior. Int J Clin Pharmacol Ther. 2013; 51: 441-442. CrossRef PubMed
20. Skopp G, Zimmer G. [Pregabalin - a drug with abuse potential?]. Arch Kriminol. 2012; 229: 44-54. PubMed
21. Yargic I, Ozdemiroglu FA. Pregabalin abuse: A case report. Bulletin of Clinical Psychopharmacology. 2011; 21: 64-66. CrossRef
22. Gahr M, Franke B, Freudenmann RW, Kölle MA, Schönfeldt-Lecuona C. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med. 2013; 7: 147-149. CrossRef PubMed
23. Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol. 2012; 32: 839-840. CrossRef PubMed
24. Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011; 52: 826-836. Cross- Ref PubMed
25. Caster O, Edwards IR, Norén GN, Lindquist M. Earlier discovery of pregabalin's dependence potential might have been possible. Eur J Clin Pharmacol. 2011; 67: 319-320. CrossRef PubMed
26. Health and Social Care information centre. Prescription Cost Analysis-England. 2012. Available from: https://catalogue.ic.nhs.uk/ publications/pre?sc?ribing/primary/pres-cost-anal-eng-2012/pres-cost-anal-eng- 2012a-rep.pdf (accessed on December 19, 2013).
27. Health IMS. U.S.: Top Medicines by Non-Discounted Spending. 2012. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/ Corporate/Press%20Room/?2012?-U.?S/?Top-Meds-Non-Discounted-Spending?-U.S.2?012. pdf (accessed on December 19, 2013).
28. Abuse and Misuse Potential of Pregabalin. A Review of the Clinical Evidence 2012. Available from: http://www.cadth.ca/media/pdf/htis/april-?20?12 (accessed on December 19, 2013).
29. Gabapentin and pregabalin: abuse and addiction. Prescrire Int. 2012; 21: 152-154. PubMed
30. Spence D. Bad medicine: gabapentin and pregabalin. BMJ. 2013; 347 (nov08 3): f6747. CrossRef PubMed
31. Satzinger G. Antiepileptics from gamma-aminobutyric acid. Arzneimittelforschung. 1994; 44: 261-266. PubMed (Pubitemid 24102545)
32. Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, Randinitis EJ, Corrigan BW, Haig GM, Boyd RA, Wesche DL. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010; 50: 941-950. CrossRef PubMed
33. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004; 45 (Suppl 6): 13-18. CrossRef PubMed (Pubitemid 39350325)
34. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007; 29: 26-48. CrossRef PubMed (Pubitemid 46415802)
35. Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia. 2011; 52: 405-409. PubMed
36. Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, Hounslow NJ, Bron NJ, Gibson GL, Bockbrader HN. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005; 46: 1407-1413. CrossRef PubMed
37. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49: 661-669. CrossRef PubMed
38. Piyapolrungroj N, Li C, Bockbrader H, Liu G, Fleisher D. Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine. Pharm Res. 2001; 18: 1126-1130. CrossRef PubMed (Pubitemid 32900397)
39. Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2013; 9: 105-115. CrossRef PubMed
40. Schmidt PC, Ruchelli G, Mackey SC, Carroll IR. Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology. 2013; 119: 1215-1221. CrossRef PubMed
41. Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs. 2012; 21: 1243-1245. CrossRef PubMed
42. Belliotti TR, Capiris T, Ekhato IV, Kinsora JJ, Field MJ, Heffner TG, Meltzer LT, Schwarz JB, Taylor CP, Thorpe AJ, Vartanian MG, Wise LD, Zhi-Su T, Weber ML, Wustrow DJ. Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein. J Med Chem. 2005; 48: 2294-2307. CrossRef PubMed (Pubitemid 40516424)
43. Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci. 2004; 20: 1566-1576. CrossRef PubMed (Pubitemid 39294695)
44. Micó JA, Prieto R. Elucidating the mechanism of action of pregabalin: á(2)ä as a therapeutic target in anxiety. CNS Drugs. 2012; 26: 637-648. CrossRef PubMed
45. Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, Walker LC. Calcium channel alpha2- delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 2006; 1075: 68-80. CrossRef PubMed
46. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007; 73: 137-150. CrossRef PubMed (Pubitemid 46329329)
47. Taylor CP, Garrido R. Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (alpha2-delta) type 1 protein. Neuroscience. 2008; 155: 510-521. CrossRef PubMed
48. Chizh BA, Göhring M, Tröster A, Quartey GK, Schmelz M, Koppert W. Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers. Br J Anaesth. 2007; 98: 246-254. CrossRef PubMed (Pubitemid 47072006)
49. Chen SR, Xu Z, Pan HL. Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. Anesthesiology. 2001; 95: 1473-1479. CrossRef PubMed (Pubitemid 33126761)
50. Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F, Cui M, Hoffman D, Donevan S. Pregabalin is a potent and selective ligand for α(2)δ-1 and α(2)δ-2 calcium channel subunits. Eur J Pharmacol. 2011; 667: 80-90. CrossRef PubMed
51. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, Chakraborty C, Mulinyawe SB, Annis DS, Huberman AD, Green EM, Lawler J, Dolmetsch R, Garcia KC, Smith SJ, Luo ZD, Rosenthal A, Mosher DF, Barres BA. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009; 139: 380-392. CrossRef PubMed
52. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T, Williams D. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006; 103: 17537-17542. CrossRef PubMed (Pubitemid 44789004)
53. McClelland D, Evans RM, Barkworth L, Martin DJ, Scott RH. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats. BMC Pharmacol. 2004; 4: 14. CrossRef PubMed
54. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure. 2003; 12: 300-306. CrossRef PubMed (Pubitemid 36806076)
55. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000; 280: 107-110. CrossRef PubMed (Pubitemid 30109144)
56. Tan KR, Brown M, Labouèbe G, Yvon C, Creton C, Fritschy JM, Rudolph U, Lüscher C. Neural bases for addictive properties of benzodiazepines. Nature. 2010; 463: 769-774. CrossRef PubMed
57. Filip M, Frankowska M. GABA(B) receptors in drug addiction. Pharmacol Rep. 2008; 60: 755-770. PubMed
58. Whitworth TL, Quick MW. Upregulation of gamma-aminobutyric acid transporter expression: role of alkylated gamma-aminobutyric acid derivatives. Biochem Soc Trans. 2001; 29: 736-741. CrossRef PubMed (Pubitemid 33131772)
59. Eckstein-Ludwig U, Fei J, Schwarz W. Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs. Br J Pharmacol. 1999; 128: 92-102. CrossRef PubMed (Pubitemid 29425272)
60. Koob GF. Addiction is a Reward Deficit and Stress Surfeit Disorder. Front Psychiatry. 2013; 4: 72. PubMed
61. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005; 8: 1445-1449. CrossRef PubMed (Pubitemid 41573654)
62. Nagakura Y, Oe T, Aoki T, Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain. 2009; 146: 26-33. CrossRef PubMed
63. Brawek B, Löffler M, Dooley DJ, Weyerbrock A, Feuerstein TJ. Differential modulation of K(+)- evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn Schmiedebergs Arch Pharmacol. 2008; 376: 301-307. CrossRef PubMed
64. Schlicker E, Reimann W, Göthert M. Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzneimittelforschung. 1985; 35: 1347-1349. PubMed (Pubitemid 15230639)
65. Freiman TM, Kukolja J, Heinemeyer J, Eckhardt K, Aranda H, Rominger A, Dooley DJ, Zentner J, Feuerstein TJ. Modulation of K+-evoked [3H]- noradrenaline release from rat and human brain slices by gabapentin: involvement of KATP channels. Naunyn Schmiedebergs Arch Pharmacol. 2001; 363: 537-542. CrossRef PubMed (Pubitemid 32417811)
66. Cole RL, Lechner SM, Williams ME, Prodanovich P, Bleicher L, Varney MA, Gu G. Differential distribution of voltage-gated calcium channel alpha- 2 delta (alpha2delta) subunit mRNA-containing cells in the rat central nervous system and the dorsal root ganglia. J Comp Neurol. 2005; 491: 246-269. CrossRef PubMed (Pubitemid 41324594)
67. Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs. 2012; 21: 1019-1029. CrossRef PubMed